Anavex adds Dr. Paul Aisen to Scientific Advisory Board
Sources News Release
Publisher: Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biot
Date Written: 16/02/2011
Year Published: 2011
Resource Type: Article
Anavex Life Sciences Corp. (OTCBB: AVXL) has announced the appointment of Dr. Paul Aisen to the Scientific Advisory Board (SAB) as a clinical expert. The SAB works closely with the company to support development of the Anavex product pipeline
Abstract: Hoboken, NJ February 16, 2011 -- Anavex Life Sciences Corp. (Anavex, AVXL.OB) today announced the appointment of Dr. Paul Aisen to the Scientific Advisory Board (SAB) as a clinical expert. The SAB works closely with the company to support development of the Anavex product pipeline, including its lead compound ANAVEX 2-73, which is being studied for Alzheimers disease and is scheduled to enter Phase I clinical trials shortly.
Dr. Aisen is a leading clinician and researcher in Alzheimers...
To read the full release go to http://www.sources.com/Releases/NR1170.htm
© 2019. The information provided is copyright and may not be reproduced in any form or by any means (whether electronic, mechanical or photographic), or stored in an electronic retrieval system, without written permission of the publisher. The content may not be resold, republished, or redistributed. Indexing and search applications by Ulli Diemer and Chris DeFreitas.